Akebia Therapeutics (AKBA) Other Accumulated Expenses (2013 - 2020)

Akebia Therapeutics (AKBA) has 8 years of Other Accumulated Expenses data on file, last reported at $452000.0 in Q1 2020.

• Other Accumulated Expenses for Q1 2020 came in at $452000.0, up 123.76% year-over-year; the trailing twelve-month figure through Mar 2020 was $452000.0 (up 123.76% YoY), and the FY2019 annual result was $9.5 million, up 141.01% from the prior year.
• Other Accumulated Expenses slipped to $452000.0 in Q1 2020 per AKBA's latest filing, from $9.5 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $9.5 million in Q4 2019 and troughed at $29000.0 in Q4 2016.
• A 5-year average of $2.0 million and a median of $452000.0 in 2020 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2017 and 2019: Other Accumulated Expenses jumped 8068.97% in 2017, then tumbled 98.66% in 2019.
• A 5-year view of Other Accumulated Expenses shows it stood at $29000.0 in 2016, then jumped by 8068.97% to $2.4 million in 2017, then soared by 67.24% to $4.0 million in 2018, then soared by 141.01% to $9.5 million in 2019, then slumped by 95.27% to $452000.0 in 2020.
• Business Quant data shows AKBA's Other Accumulated Expenses at $452000.0 in Q1 2020, $9.5 million in Q4 2019, and $79000.0 in Q3 2019.